Food and Drug Administration and Pharmaceutical Issues
ASN advocates with the US Food and Drug Administration, Congress, and other entities to ensure that patients with kidney disease have reasonable access to safe, high-quality medications and other therapies.
- ASN Sign-on Letter to FDA Supporting Midodrene Hydrochloride
- ASN Letter to FDA Supporting Midodrene Hydrochloride
- Presentation on ESA Label Changes
- ASN Letter to FDA and FSIS on Strategies to Reduce Sodium Intake
- ASN FDA Food Labeling Comment Letter
- ASN, NKF Joint FDA Food Labeling Comment Letter
- ASN Urges FDA to Expedite Solution to Shortage of PD Solution
- FDA Responds to ASN Letter Regarding PD Solution Shortage
- Temporary Importation of DIANEAL Solution for PD
- ASN Support for New FDA Office of Patient Engagement